Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium: a prospective cross-sectional study of residual samples
暂无分享,去创建一个
N. Hens | P. Beutels | N. Hens | P. Beutels | P. van Damme | S. Herzog | H. Theeten | S. Abrams | P. Van Damme | S. Abrams | S. Herzog | J. De Bie | I. Wouters | E. Ekinci | L. Patteet | A. Coppens | S. De Spiegeleer | H. Theeten | A. Coppens | J. De Bie | I. Wouters | Esra Ekinci | Lisbeth Patteet | Sandy De Spiegeleer
[1] Verena van der Heide. Neutralizing antibody response in mild COVID-19 , 2020 .
[2] Thomas Lumley,et al. Analysis of Complex Survey Samples , 2004 .
[3] Marco D'Arienzo,et al. Assessment of the SARS-CoV-2 basic reproduction number, R0, based on the early phase of COVID-19 outbreak in Italy , 2020, Biosafety and Health.
[4] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[5] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[6] Validation of a commercially available SARS-CoV-2 serological immunoassay , 2020, Clinical Microbiology and Infection.
[7] Y. Wen,et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications , 2020, medRxiv.
[8] A. Iafrate,et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients , 2020, Science Immunology.
[9] J. Rocklöv,et al. The reproductive number of COVID-19 is higher compared to SARS coronavirus , 2020, Journal of travel medicine.
[10] E. Stoneman,et al. The Novel Coronavirus: A Bird's Eye View , 2020, The international journal of occupational and environmental medicine.
[11] Miriam Merad,et al. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages , 2020, Nature Reviews Immunology.
[12] M. Malim,et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans , 2020, Nature Microbiology.
[13] S. Lo,et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.
[14] D. W. Maybury,et al. A note on COVID-19 seroprevalence studies: a meta-analysis using hierarchical modelling , 2020, medRxiv.
[15] K. Krogfelt,et al. Evaluation of nine commercial SARS-CoV-2 immunoassays , 2020, medRxiv.
[16] H. Gidding. Australia's national serosurveillance program. , 2003, New South Wales public health bulletin.
[17] D. Buckeridge,et al. SeroTracker: a global SARS-CoV-2 seroprevalence dashboard , 2020, The Lancet Infectious Diseases.
[18] Daniel M Altmann,et al. What policy makers need to know about COVID-19 protective immunity , 2020, The Lancet.
[19] Kai Liu,et al. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients , 2020, Journal of Infection.
[20] P. van Damme,et al. Universal hepatitis B vaccination in Belgium: impact on serological markers 3 and 7 years after implementation , 2013, Epidemiology and Infection.